The European Journal of Health Economics

, Volume 13, Issue 4, pp 511–524 | Cite as

Cost of care for colorectal cancer in Ireland: a health care payer perspective

  • L. Tilson
  • L. Sharp
  • C. Usher
  • C. Walsh
  • Whyte S
  • A. O’Ceilleachair
  • C. Stuart
  • B. Mehigan
  • M. John Kennedy
  • P. Tappenden
  • J. Chilcott
  • A. Staines
  • H. Comber
  • M. Barry
Original Paper



Management options for colorectal cancer have expanded in recent years. We estimated average lifetime cost of care for colorectal cancer in Ireland in 2008, from the health care payer perspective.


A decision tree model was developed in Microsoft EXCEL. Site and stage-specific treatment pathways were constructed from guidelines and validated by expert clinical opinion. Health care resource use associated with diagnosis, treatment and follow-up were obtained from the National Cancer Registry Ireland (n=1,498 cancers diagnosed during 2004–2005) and three local hospital databases (n=155, 142 and 46 cases diagnosed in 2007). Unit costs for hospitalisation, procedures, laboratory tests and radiotherapy were derived from DRG costs, hospital finance departments, clinical opinion and literature review. Chemotherapy costs were estimated from local hospital protocols, pharmacy departments and clinical opinion. Uncertainty was explored using one-way and probabilistic sensitivity analysis.


In 2008, the average (stage weighted) lifetime cost of managing a case of colorectal cancer was €39,607. Average costs were 16% higher for rectal (€43,502) than colon cancer (€37,417). Stage I disease was the least costly (€23,688) and stage III most costly (€48,835). Diagnostic work-up and follow-up investigations accounted for 4 and 5% of total costs, respectively. Cost estimates were most sensitive to recurrence rates and prescribing of biological agents.


This study demonstrates the value of using existing data from national and local databases in contributing to estimating the cost of managing cancer. The findings illustrate the impact of biological agents on costs of cancer care and the potential of strategies promoting earlier diagnosis to reduce health care resource utilisation and care costs.


Colorectal cancer Cost Health care resources Chemotherapy 

JEL Classification

I10 I11 



We are grateful to the Expert Advisory Group, HTA Directorate and Board of the Health Information and Quality Authority for their input into this study. The views expressed are not necessarily those of the Health Information and Quality Authority. We are particularly grateful to those individuals who provided data. We would also like to thank numerous individuals for helpful discussions and input; these individuals are listed in the full HTA report (available at: [25]. This study was funded by the Health Information and Quality Authority and the Health Research Board. The authors have no conflicts of interest to declare.


  1. 1.
    Jansman, F., Postma, M., Brouwers, J.: Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 25, 537–562 (2007)CrossRefPubMedGoogle Scholar
  2. 2.
    Brown, M., Riley, G., Potosky, A., Etzioni, R.: Obtaining long-term disease specific costs of care: application to medicare enrollees diagnosed with colorectal cancer. Med. Care 37, 1249–1259 (1999)CrossRefPubMedGoogle Scholar
  3. 3.
    Clerc, L., Joosts, V., Lejeune, C., et al.: Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur J Health Econ 9, 361–367 (2008)CrossRefPubMedGoogle Scholar
  4. 4.
    Warren, J., Yabroff, K., Meekins, A., Topor, M., Lamont, E., Brown, M.: Evaluation of trends in the cost of initial cancer treatment. J. Natl Cancer Inst. 100, 888–897 (2008)CrossRefPubMedGoogle Scholar
  5. 5.
    Benson, A.: Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 13, S5–S18 (2007)PubMedGoogle Scholar
  6. 6.
    Delco, F., Egger, R., Bauerfeind, P., Beglinger, C.: Hospital health care resource utilisation and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland. Aliment. Pharmacol. Ther. 21, 615–622 (2005)CrossRefPubMedGoogle Scholar
  7. 7.
    Jonnson, B., Wilking, N.: A global comparison regarding patient access to cancer drugs. Ann. Oncol. 18(Suppl 3), 1–77 (2007)Google Scholar
  8. 8.
    Kanavos, P., Schurer, W.: The burden of colorectal cancer: prevention, treatment and quality of services. Eur J Health Econ 10(Suppl 1), S1–S3 (2010)CrossRefPubMedGoogle Scholar
  9. 9.
    Kanavos, P., Schurer, W.: The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ 10(Suppl 1), S115–S129 (2010)CrossRefPubMedGoogle Scholar
  10. 10.
    Parkin, D.M., Bray, F., Pisani, P.: Global cancer statistics, 2002. CA Cancer J Clin 55, 74–108 (2005)CrossRefPubMedGoogle Scholar
  11. 11.
    International Agency for Research on Cancer. Colorectal cancer incidence and mortality worldwide in 2008 (, 2008. Accessed Jan 2011
  12. 12.
    National Cancer Registry. Trends in Irish cancer incidence 1994–2002, with projections to 2020. Report of the National Cancer Registry, Cork, Ireland (, 2006. Accessed April 2010
  13. 13.
    Verdecchia, A., Guzzinati, S., Francisci, S., et al.: EUROCARE working group survival trends in European cancer patients diagnosed from 1988 to 1999. Eur. J. Cancer 45, 1042–1066 (2009)CrossRefPubMedGoogle Scholar
  14. 14.
    Kuhry, E., Schwenk, W., Gaupset, R., Romild, U., Bonjer, J.: Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. Cancer Treat. Rev. 34, 498–504 (2008)CrossRefPubMedGoogle Scholar
  15. 15.
    Salz, T., Sander, R.S.: The effect of hospital and surgeon volume on outcomes for rectal cancer surgery. Clin Gastroenterol Hepatol 6, 1185–1193 (2008)CrossRefPubMedGoogle Scholar
  16. 16.
    Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systematic overview of 8, 507 patients from 22 randomised trials. Lancet 358, 1291–1304 (2001)CrossRefGoogle Scholar
  17. 17.
    Sauer, R., Becker, H., Hohenberger, W., et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731–1740 (2004)CrossRefPubMedGoogle Scholar
  18. 18.
    Scottish Intercollegiate Guidelines Network (SIGN). Management of colorectal cancer. A national clinical guideline. No.67 (, 2003. Accessed March 2010
  19. 19.
    Australian Cancer Network Colorectal Cancer Guidelines Revision Committee: Guidelines for the prevention, early detection and management of colorectal cancer, 2nd edn. The Cancer Council Australia and Australian Cancer Network, Sydney (2005)Google Scholar
  20. 20.
    National Institute for Health and Clinical Excellence. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer. NICE Technology Appraisal 61 (, 2003. Accessed March 2010
  21. 21.
    National Institute for Health and Clinical Excellence. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Review of technology appraisal 33.Technology Appraisal 93 (, 2005. Accessed March 2010
  22. 22.
    Gravalos, C., Garcia-Escobar, I., Garcia-Alfonso, P., Cassinello, J., Malon, D., Carrato, A.: Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin. Transl. Oncol. 11, 526–533 (2009)CrossRefPubMedGoogle Scholar
  23. 23.
    Andre, T., Sargent, D., Tabernero, J., et al.: Current issues in adjuvant treatment of stage II colon cancer. Ann. Surg. Oncol. 13, 887–898 (2006)CrossRefPubMedGoogle Scholar
  24. 24.
    Rajpal, S., Venook, A.P.: Targeted therapy in colorectal cancer. Clin Adv Hematol Oncol 4, 124–132 (2006)PubMedGoogle Scholar
  25. 25.
    Health Information and Quality Authority. A health technology assessment of a population-based colorectal cancer screening programme in Ireland (, 2009. Accessed April 2010
  26. 26.
    National Comprehensive Cancer Network. Rectal cancer clinical practice guidelines in oncology (Version 1)(2006b) (, Accessed April 2010
  27. 27.
    National Comprehensive Cancer Network. Colon cancer Clinical Practice Guidelines in Oncology (Version 1)(2006a) (, Accessed March 2010
  28. 28.
    Association of Coloproctology of Great Britain and Ireland: Guidelines for the management of colorectal cancer. 3rd Edn. (2007) (, Accessed April 2010
  29. 29.
    Segnan, N., Senore, C., Andreoni, B., et al.: SCORE 2 Working Group-Italy. Baseline findings of the Italian multicenter randomised controlled trial of “once-only sigmoidoscopy”. J. Natl Cancer Inst. 94, 1763–1772 (2005)CrossRefGoogle Scholar
  30. 30.
    Shah, H., Paszat, L., Saskin, R., Stukel, T., Rabeneck, L.: Factors associated with incomplete colonoscopy: a population-based study. Gastroenterology 132, 2297–2303 (2007)CrossRefPubMedGoogle Scholar
  31. 31.
    Di Gregorio, C., Benatti, P., Losi, L., et al.: Incidence and survival of patients with Dukes’ A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study. Int. J. Colorectal Dis. 20, 147–154 (2005)CrossRefPubMedGoogle Scholar
  32. 32.
    Kapiteijn, E., Marijnen, C.A., Colenbrander, A.C., et al.: Local recurrence in patients with rectal cancer diagnosed between 1988 and 1992: A population-based study in the west Netherlands. Eur. J. Surg. Oncol. 24, 528–535 (1998)CrossRefPubMedGoogle Scholar
  33. 33.
    Manfredi, S., Bouvier, A., Lepage, C., Hatem, C., Dancourt, V., Faivre, J.: Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br. J. Surg. 93, 1115–1122 (2006)CrossRefPubMedGoogle Scholar
  34. 34.
    Påhlman, L., Bohe, M., Cedermark, B., et al.: The Swedish rectal cancer registry. Br. J. Surg. 94, 1285–1292 (2007)CrossRefPubMedGoogle Scholar
  35. 35.
    Sjovall, A., Granath, F., Cedermark, B., Glimelius, B., Holm, T.: Loco-regional recurrence from colon cancer: A population-based study. Ann. Surg. Oncol. 14, 432–440 (2007)CrossRefPubMedGoogle Scholar
  36. 36.
    Wibe, A., Carlsen, E., Dahl, O., et al.: Nationwide quality assurance of rectal cancer treatment. Colorectal Dis 8, 224–229 (2006)CrossRefPubMedGoogle Scholar
  37. 37.
    Heriot, A., Kumar, D.: Rectal cancer recurrence: factors and mechanisms. Colorectal Dis 2, 126–136 (2000)CrossRefGoogle Scholar
  38. 38.
    de Zeeuw, N., Keane, F., Neary, P.: Nurse-led protocol driven colorectal cancer follow-up clinic. Mod Med Irish J Clin Med 37, 16–19 (2007)Google Scholar
  39. 39.
    Tappenden P, Eggington S, Nixon R, Chilcott J, Sakai H, Karnon J.: Colorectal cancer screening options appraisal: cost-effectiveness, cost-utility and resource impact of alternative screening options for colorectal cancer. Report to the English Bowel Cancer Working Group (2004)Google Scholar
  40. 40.
    Tappenden, P., Chilcott, J., Eggington, S., Sakai, H., Karnon, J., Patnick, J.: Option appraisal of population-based colorectal cancer screening programmes in England. Gut 56, 677–684 (2007)CrossRefPubMedGoogle Scholar
  41. 41.
    Health Information and Quality Authority. Draft guidelines for the economic evaluation of health technologies in Ireland (, 2010. Accessed August 2010
  42. 42.
    Health Service Executive (HSE) Casemix Unit: Ready reckoner of acute hospital inpatient activity and costs (summarised by DRG) relating to 2006 costs and activity. Annual Report Part 3. (2008)Google Scholar
  43. 43.
    Ploquin, N., Dunscombe, P.: The cost of radiation therapy. Radiother. Oncol. 86, 217–223 (2008)CrossRefPubMedGoogle Scholar
  44. 44.
    Guest, J., Ruiz, F., Greener, M., Trotman, I.: Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care 15, 65–73 (2006)CrossRefGoogle Scholar
  45. 45.
    Monthly Index of Medical Specialities (MIMS): Ireland. (August 2008)Google Scholar
  46. 46.
    National Cancer Registry. Cancer in Ireland, 1994 to 1998: incidence, mortality, treatment and survival. Report of the National Cancer Registry, Cork, Ireland (, 2001. Accessed April 2010
  47. 47.
    Neymark, N., Adriaenssen, I.: The costs of managing patients with advanced colorectal cancer in 10 different European centres. Eur. J. Cancer 35, 1789–1795 (1999)CrossRefPubMedGoogle Scholar
  48. 48.
    Timmons, A., Sharp, L., Carsin, A.E., et al.: The cost of having cancer: a survey of patients with cancer in Ireland. J. Epidemiol. Community Health 63(Suppl 2), 46 (2009)CrossRefGoogle Scholar
  49. 49.
    Drolet, M., Maunsell, E., Mondor, M., et al.: Work absence after breast cancer diagnosis: a population-based study. CMAJ 173, 765–771 (2005)CrossRefPubMedGoogle Scholar
  50. 50.
    Bradley, C.J., Oberst, K., Schenk, M.: Absenteeism from work: the experience of employed breast and prostate cancer patients in the months following diagnosis. Psychooncology 15, 739–747 (2006)CrossRefPubMedGoogle Scholar
  51. 51.
    Paramore, L., Thomas, S., Knopf, K., et al.: Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer 6, 52–58 (2006)CrossRefPubMedGoogle Scholar
  52. 52.
    Fireman, B.H., Quesenberry, C.P., Somkin, C.P., et al.: Costs of care for cancer in a health maintenance organisation. Health Care Financ Rev 18, 51–76 (1997)PubMedGoogle Scholar
  53. 53.
    Ramsey, S.D., Berry, K., Etzioni, R.: Lifetime cancer-attributable cost of care for long-term survivors of colorectal cancer. Am. J. Gastroenterol. 97, 440–445 (2002)CrossRefPubMedGoogle Scholar
  54. 54.
    Bouhier, K., Maurel, J., Lefevre, H., Bouin, M., Asrsene, D., Launoy, G.: Changing practices for diagnosis and treatment of colorectal cancer in Calvados: 1990–1999. Gastroenterol Clin Biol 28, 371–376 (2004)CrossRefPubMedGoogle Scholar
  55. 55.
    Van Steenbergen LN, Elferink MA, Krijnen P, et al.: Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989–2006. Ann Oncol. 2010 May 3 [Epub ahead of print]Google Scholar
  56. 56.
    Carsin, A.E., Sharp, L., Cronin-Fenton, D., O’Ceilleachair, A., Comber, H.: Inequity in colorectal cancer treatment and outcomes: a population-based study. Br. J. Cancer 99, 266–274 (2008)CrossRefPubMedGoogle Scholar
  57. 57.
    Schrag, D.: The price tag on progress: chemotherapy for colorectal cancer. NEJM 351, 317–319 (2004)CrossRefPubMedGoogle Scholar
  58. 58.
    Patil, D., Fraser, C., Plesec, T.: KRAS testing and its importance in colorectal cancer. Curr Oncol Rep 12, 160–167 (2010)CrossRefPubMedGoogle Scholar
  59. 59.
    Feliu, J., Safont, M.J., Salud, A., Losa, F., Garcia-Giron, C., et al.: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br. J. Cancer 102, 1468–1473 (2010)CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • L. Tilson
    • 1
  • L. Sharp
    • 2
  • C. Usher
    • 1
  • C. Walsh
    • 1
    • 3
  • Whyte S
    • 4
  • A. O’Ceilleachair
    • 2
  • C. Stuart
    • 5
  • B. Mehigan
    • 5
  • M. John Kennedy
    • 5
    • 6
  • P. Tappenden
    • 4
  • J. Chilcott
    • 4
  • A. Staines
    • 7
  • H. Comber
    • 2
  • M. Barry
    • 1
  1. 1.National Centre for Pharmacoeconomics, St James’s HospitalDublin 8Ireland
  2. 2.National Cancer Registry Ireland, Cork Airport Business ParkCorkIreland
  3. 3.Department of Statistics, Trinity College DublinDublinIreland
  4. 4.School for Health and Related ResearchUniversity of SheffieldSheffieldUK
  5. 5.St James’s HospitalDublinIreland
  6. 6.Academic Unit of Clinical and Molecular OncologyTrinity College DublinDublinIreland
  7. 7.School of NursingDublin City UniversityDublinIreland

Personalised recommendations